Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hemofiltration and plasma dopamine beta-hydroxylase activity

U Spohr, H W Schneider, E Streicher

    Nephron
    |January 1, 1980
    PubMed
    Summary

    Plasma dopamine beta-hydroxylase (DBH) activity is significantly lower in patients undergoing maintenance hemodialysis or hemofiltration compared to healthy controls. The observed changes in DBH levels during these procedures are likely due to hemoconcentration.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    De novo glomerulonephritis in patients during remission from Wegener's granulomatosis.

    Clinical nephrology·1992
    Same author

    Reduced capillary density in the myocardium of uremic rats--a stereological study.

    Kidney international·1992
    Same author

    Renal histology in polycystic kidney disease with incipient and advanced renal failure.

    Kidney international·1992
    Same author

    The effect of uninephrectomy on progression of renal failure in autosomal dominant polycystic kidney disease.

    Journal of the American Society of Nephrology : JASN·1992
    Same author

    Severe hemorrhagic complications from infection with nephropathia epidemica strain of Hantavirus.

    Clinical nephrology·1992
    Same author

    Disturbed calcium metabolism in renal failure--pathogenesis and therapeutic strategies.

    Kidney international. Supplement·1992

    Area of Science:

    • Neuropeptide and enzyme activity research
    • Renal replacement therapy
    • Biochemical markers in chronic kidney disease

    Background:

    • Dopamine beta-hydroxylase (DBH) is a key enzyme in catecholamine synthesis.
    • Chronic kidney disease patients often exhibit altered enzyme activities.
    • Renal replacement therapies like hemodialysis and hemofiltration are standard treatments.

    Purpose of the Study:

    • To investigate plasma dopamine beta-hydroxylase (DBH) activity in patients undergoing maintenance hemodialysis and hemofiltration.
    • To compare DBH levels between these patient groups and healthy controls.
    • To explore the dynamic changes in DBH activity during renal replacement therapy sessions.

    Main Methods:

    • Plasma DBH activity was measured in three groups: healthy controls (n=70), hemodialysis patients (n=79), and hemofiltration patients (n=19).

    Related Experiment Videos

  • DBH activity was assessed during and between renal replacement therapy sessions.
  • Seven patients underwent both hemodialysis and hemofiltration sessions with identical fluid balance for comparative analysis.

    • Main Results:

    • Plasma DBH activity was significantly lower in both hemodialysis (32.4 +/- 20.6 IU) and hemofiltration (32.8 +/- 29.7 IU) patients compared to controls (50.0 +/- 29.3 IU).
    • Sequential measurements in hemofiltration patients did not reveal a decline in DBH activity over time.
    • The rise in DBH activity observed during a single hemodialysis or hemofiltration session was not significantly different between the two modalities and could be attributed to hemoconcentration.

    Conclusions:

    • Patients on maintenance hemodialysis and hemofiltration exhibit reduced plasma DBH activity.
    • The observed fluctuations in DBH activity during renal replacement therapy are likely a consequence of hemoconcentration rather than a direct effect of the therapy on enzyme levels.
    • DBH may serve as a potential, albeit indirect, marker related to fluid status in patients undergoing renal replacement therapy.